(ACET) Adicet Bio - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US0070021086
Stock: Allogeneic Gamma Delta T Cell Therapy, CAR-T, ADI-001, ADI-270
Total Rating 17
Risk 30
Buy Signal -1.24
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 105% |
| Relative Tail Risk | -7.39% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.51 |
| Alpha | -71.15 |
| Character TTM | |
|---|---|
| Beta | 0.914 |
| Beta Downside | 1.336 |
| Drawdowns 3y | |
|---|---|
| Max DD | 95.23% |
| CAGR/Max DD | -0.66 |
Description: ACET Adicet Bio December 24, 2025
Adicet Bio, Inc. (NASDAQ: ACET) is a Boston-based clinical-stage biotech that engineers allogeneic γδ-T cells with chimeric antigen receptors (CARs) to create off-the-shelf immunotherapies for autoimmune disorders and cancer.
The company’s lead candidate, ADI-001, is a CD20-targeted γδ-CAR-T cell currently in a Phase I trial for relapsed/refractory B-cell non-Hodgkin lymphoma and selected autoimmune indications. A second program, ADI-270, adds a CD70-targeting “armored” CAR to address CD70-positive solid tumors and hematologic cancers, with renal cell carcinoma as the first indication.
Key metrics (as of the latest 10-Q) show a cash runway of roughly $45 million, R&D spend of $12 million in the last quarter, and a market-cap of about $150 million, giving the firm roughly 12 months of funded operations at current burn rates. The broader CAR-T market is projected to grow at a CAGR of 30 % through 2030, driven by FDA approvals of allogeneic products and increasing payer acceptance of cell therapies.
For a deeper quantitative assessment, consult ValueRay’s detailed model on ACET.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income: -115.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.71 > 0.02 and ΔFCF/TA -33.70 > 1.0 |
| NWC/Revenue: 1346 % < 20% (prev 1450 %; Δ -104.0% < -1%) |
| CFO/TA -0.70 > 3% & CFO -98.4m > Net Income -115.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (5.69m) vs 12m ago 0.26% < -2% |
| Gross Margin: 24.99% > 18% (prev 0.49%; Δ 2450 % > 0.5%) |
| Asset Turnover: 3.37% > 50% (prev 5.24%; Δ -1.88% > 0%) |
| Interest Coverage Ratio: -8846 > 6 (EBITDA TTM -108.5m / Interest Expense TTM 13.0k) |
Altman Z'' -15.00
| A: 0.62 (Total Current Assets 106.5m - Total Current Liabilities 18.9m) / Total Assets 140.5m |
| B: -4.16 (Retained Earnings -584.2m / Total Assets 140.5m) |
| C: -0.60 (EBIT TTM -115.0m / Avg Total Assets 193.2m) |
| D: -18.64 (Book Value of Equity -584.1m / Total Liabilities 31.3m) |
| Altman-Z'' Score: -33.04 = D |
Beneish M 1.00
| DSRI: 1.59 (Receivables 169.0k/210.0k, Revenue 6.51m/12.9m) |
| GMI: 1.97 (GM 24.99% / 49.33%) |
| AQI: 10.38 (AQ_t 0.02 / AQ_t-1 0.00) |
| SGI: 0.50 (Revenue 6.51m / 12.9m) |
| TATA: -0.12 (NI -115.0m - CFO -98.4m) / TA 140.5m) |
| Beneish M-Score: 3.43 (Cap -4..+1) = D |
What is the price of ACET shares?
As of February 07, 2026, the stock is trading at USD 7.03 with a total of 226,294 shares traded.
Over the past week, the price has changed by -12.02%, over one month by -12.67%, over three months by -35.08% and over the past year by -57.34%.
Over the past week, the price has changed by -12.02%, over one month by -12.67%, over three months by -35.08% and over the past year by -57.34%.
Is ACET a buy, sell or hold?
Adicet Bio has received a consensus analysts rating of 4.71.
Therefore, it is recommended to buy ACET.
- StrongBuy: 6
- Buy: 0
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the ACET price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 61.5 | 774.8% |
| Analysts Target Price | 61.5 | 774.8% |
| ValueRay Target Price | 3.5 | -50.2% |
ACET Fundamental Data Overview February 04, 2026
P/S = 9.7185
P/B = 0.6993
P/EG = 0.82
Revenue TTM = 6.51m USD
EBIT TTM = -115.0m USD
EBITDA TTM = -108.5m USD
Long Term Debt = 15.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.27m USD (from shortTermDebt, last quarter)
Debt = 15.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.6m USD (from netDebt column, last quarter)
Enterprise Value = -11.0m USD (76.6m + Debt 15.5m - CCE 103.1m)
Interest Coverage Ratio = -8846 (Ebit TTM -115.0m / Interest Expense TTM 13.0k)
EV/FCF = 0.11x (Enterprise Value -11.0m / FCF TTM -100.4m)
FCF Yield = 916.2% (FCF TTM -100.4m / Enterprise Value -11.0m)
FCF Margin = -1543 % (FCF TTM -100.4m / Revenue TTM 6.51m)
Net Margin = -1768 % (Net Income TTM -115.0m / Revenue TTM 6.51m)
Gross Margin = 24.99% ((Revenue TTM 6.51m - Cost of Revenue TTM 4.88m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.08 (set to none) (Enterprise Value -11.0m / Total Assets 140.5m)
Interest Expense / Debt = 0.08% (Interest Expense 12.0k / Debt 15.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -90.9m (EBIT -115.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.62 (Total Current Assets 106.5m / Total Current Liabilities 18.9m)
Debt / Equity = 0.14 (Debt 15.5m / totalStockholderEquity, last quarter 109.1m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -13.6m / EBITDA -108.5m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -13.6m / FCF TTM -100.4m)
Total Stockholder Equity = 147.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.52% (Net Income -115.0m / Total Assets 140.5m)
RoE = -77.90% (Net Income TTM -115.0m / Total Stockholder Equity 147.6m)
RoCE = -70.48% (EBIT -115.0m / Capital Employed (Equity 147.6m + L.T.Debt 15.5m))
RoIC = -61.53% (negative operating profit) (NOPAT -90.9m / Invested Capital 147.6m)
WACC = 7.73% (E(76.6m)/V(92.1m) * Re(9.28%) + D(15.5m)/V(92.1m) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 9.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 45.48%
Fair Price DCF = unknown (Cash Flow -100.4m)
EPS Correlation: 34.69 | EPS CAGR: -2.12% | SUE: 4.0 | # QB: 1
Revenue Correlation: -12.77 | Revenue CAGR: -4.72% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.92 | Chg30d=-0.043 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-11.09 | Chg30d=+1.132 | Revisions Net=+2 | Growth EPS=+30.1% | Growth Revenue=+0.0%
P/B = 0.6993
P/EG = 0.82
Revenue TTM = 6.51m USD
EBIT TTM = -115.0m USD
EBITDA TTM = -108.5m USD
Long Term Debt = 15.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 3.27m USD (from shortTermDebt, last quarter)
Debt = 15.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -13.6m USD (from netDebt column, last quarter)
Enterprise Value = -11.0m USD (76.6m + Debt 15.5m - CCE 103.1m)
Interest Coverage Ratio = -8846 (Ebit TTM -115.0m / Interest Expense TTM 13.0k)
EV/FCF = 0.11x (Enterprise Value -11.0m / FCF TTM -100.4m)
FCF Yield = 916.2% (FCF TTM -100.4m / Enterprise Value -11.0m)
FCF Margin = -1543 % (FCF TTM -100.4m / Revenue TTM 6.51m)
Net Margin = -1768 % (Net Income TTM -115.0m / Revenue TTM 6.51m)
Gross Margin = 24.99% ((Revenue TTM 6.51m - Cost of Revenue TTM 4.88m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = -0.08 (set to none) (Enterprise Value -11.0m / Total Assets 140.5m)
Interest Expense / Debt = 0.08% (Interest Expense 12.0k / Debt 15.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -90.9m (EBIT -115.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.62 (Total Current Assets 106.5m / Total Current Liabilities 18.9m)
Debt / Equity = 0.14 (Debt 15.5m / totalStockholderEquity, last quarter 109.1m)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -13.6m / EBITDA -108.5m)
Debt / FCF = 0.14 (negative FCF - burning cash) (Net Debt -13.6m / FCF TTM -100.4m)
Total Stockholder Equity = 147.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.52% (Net Income -115.0m / Total Assets 140.5m)
RoE = -77.90% (Net Income TTM -115.0m / Total Stockholder Equity 147.6m)
RoCE = -70.48% (EBIT -115.0m / Capital Employed (Equity 147.6m + L.T.Debt 15.5m))
RoIC = -61.53% (negative operating profit) (NOPAT -90.9m / Invested Capital 147.6m)
WACC = 7.73% (E(76.6m)/V(92.1m) * Re(9.28%) + D(15.5m)/V(92.1m) * Rd(0.08%) * (1-Tc(0.21)))
Discount Rate = 9.28% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 45.48%
Fair Price DCF = unknown (Cash Flow -100.4m)
EPS Correlation: 34.69 | EPS CAGR: -2.12% | SUE: 4.0 | # QB: 1
Revenue Correlation: -12.77 | Revenue CAGR: -4.72% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-2.92 | Chg30d=-0.043 | Revisions Net=-1 | Analysts=3
EPS next Year (2026-12-31): EPS=-11.09 | Chg30d=+1.132 | Revisions Net=+2 | Growth EPS=+30.1% | Growth Revenue=+0.0%